ETST Website  |  About  |  Products  |  I.R.                                                        Get FinancialNewsMedia.com Alerts 

Privacy Policy

Earth Science Tech, Inc. (OTC: ETST) Breaking News - June 13, 2017

 


Earth Science Tech, Inc. Announces New Wholly-Owned Subsidiary, KannBidioid Inc., to Manufacture & Distribute Vapes/E-Liquids & Gummy Edibles to Vape/Smoke Shops 



Hollywood, June 13, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis CBD-based (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices is pleased to announce its new wholly owned subsidiary KannaBidioid Inc. to manufacture and distribute vapes/e-liquids and gummy edibles to target vape/smoke shops.

After a successful May, 2017, launch of ETST’s new products: Strawberry Orange Blossom CBD oil, CBD Organic Chocolate line, and Pet CBD oil, ETST’s management team came across an opportunity to step into the recreational vape/smoke space. Earth Science is excited to announce it will begin to formulate, produce and sell Kanna-infused cannabidiol (CBD) based e-liquids and gummy edibles, hence KannaBidioid, Inc. (KBD).

Kanna (Sceletium tortuosum) is known to elevate mood, decrease anxiety, stress and tension, and suppress the appetite. In moderate doses, it induces euphoria and acts as a powerful stimulant, but can actually have a sedative effect in larger doses.

“Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus, and help with nicotine addiction based on their properties,” stated Dr. Michel Aube, ETST’s CEO & CSO. Dr. Aube elaborates with, "CBD is a strong antioxidant that enhances well-being, among other properties, by reducing the oxidative stress produced by the human brain through its elivated metabolic activity. While Kanna might also have anxiolytic potential, as it modulates the biological activity of serotonin, the two together will significantly reduce anxiety as the Hemp Oil will create better physiological conditions for the biological activity of the Kanna extract. All together, the full spectrum of the Hemp Oil and full spectrum of the Kanna plant have the potential to better regulate the activity of serotonin, gicing a more powerful sensation of satisfaction than any other plant extract used alone."

ETST president, director, and COO, Nickolas S. Tabraue stated, “forming our new subsidiary we can now enter the recreational vape/smoke shop space with not just CBD but, a unique Kanna CBD blend giving us a niche in the market having us now compete with the likes of (OTC Pink: POTN), (OTC Pink: MJNA), (OTC Pink: MCOA), and (OTCQB: CBDS) while discovering and building new revenue streams. Forming KannaBidioid allows us to enter this space without damaging our medicinal ETST image that has been so successful for us. We are currently working on flavors and package design on both vape/e-liquids and gummy edibles, and look to launch within Q4 while updating our stakeholders as we progress.” He continued, “We are currently still moving in a positive direction with some major domestic and international distributors for our current full CBD line and have been getting amazing feedback on our new products as well as increasing order and new stores carrying our products.” Mr. Tabraue concluded by sharing his experience at SeeThruEquity’s 6th annual conference in New York, “I had the pleasure to share our story and brand to a lot of great individuals at the SeeThruEquity conference and got nothing but, amazing feedback and have started talks with a few key individuals that can potentially work synergistically with ETST and I plan on sharing updates as talks continue and structures have been made.”

About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. To find out more information on all our research please visit our website: www.earthsciencetech.com

ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a wellknown dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include: • Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/newsrelease/2015/12/09/794223/0/en/Earth-Science-Tech-Announces-the-Conclusion-of-Phase-1-Trial-withFormer-Professional-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html)

• Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/10/29/781678/0/en/EarthScience-Tech-Starts-30-day-Trial-Study-with-Former-Professional-Football-Athletes-Using-ETST-HighGrade-Hemp-CBD-Cannabidiol.html)

• Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection. (https://globenewswire.com/newsrelease/2015/10/20/777795/0/en/Earth-Science-Tech-Files-International-PCT-on-its-Hemp-CBDCannabidiol-Invention-and-Provisional-Patent-Cannabidiol-Compositions-Including-Mixtures-and-UsesThereof-Related-to-Trea.html)

• Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol
(CBD). (https://globenewswire.com/news-release/2015/10/16/776942/0/en/Earth-Science-TechAnnounces-Case-Studies-to-Begin-With-Former-Pro-Athletes.html)

• DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-sciencetech-etst-high-grade-hemp-otcqb-etst-2032087.htm)

• DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-sciencetech-etst-high-grade-hemp-otcqb-etst-2032087.htm)

• Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function. (http://www.marketwired.com/press-release/earth-science-tech-announcespositive-test-results-its-product-cbd-cannabidiol-rich-otcqb-etst-1985844.htm)

• Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD(Cannabidiol) Rich Hemp Oil Because of Its Findings with the University of Central Oklahoma and the Effects of CBD on Immune Cells. (http://www.marketwired.com/press-release/earth-science-tech-secures-ground-breakingsecond-provisional-patent-its-cbd-cannabidiol-otcqb-etst-1983756.htm)

• Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-preliminary-test-resultson-effects-its-hemp-oil-otcqb-etst-1956064.htm)

• ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells. (http://www.marketwired.com/press-release/etst-collegemathematics-science-university-central-oklahoma-join-forces-joint-effort-otcqb-etst-1949268.htm)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com

The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology
company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Cannabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The THREE (3) cannabis cannabinoidbased nutraceutical patents and TWO (2) generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forwardlooking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Dave Demarest (305)-546-7640

Earth Science Tech, Inc. Nickolas S. Tabraue, P/D/COO

(305)-615-2118

Source: Earth Science Tech, Inc.


-------------------------------------------------------------------
Recent Earth Science Tech News:

 

Earth Science Tech, Inc. Presents at SeeThruEquity Microcap Investor’s 6th Annual Conference in New York June 1st



Hollywood, May 25, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis CBD-based (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices and its subsidiary, Cannabis Therapeutics Inc., will attend and present at SeeThruEquity Microcap Investor’s 6th Annual Conference in New York June 1st.

ETST will attend and present at the SeeThruEquity’s 6th annual conference. The Company will meet one on one with scheduled accredited investors, and network with other companies such as AXIM Biotechnologies, Inc. (OTCQB: AXIM), Massroots, Inc. (OTCQB: MSRT), Potnetwork Holding, Inc. (OTCPink: POTN), and many others.

SeeThruEquity (STE) has been committed to its core mission: providing impactful, high quality research on uncovered and under covered microcap stocks and hosting investor conferences throughout the year. STE has been able to grow its research universe to over 190 names.

STE conferences can be pivotal events for publicly traded companies with less than $1 billion in market capitalization. STE augments the conference experience with the firm's research which is part of Wall Street consensus and available across industry leading platforms including Thomson First Call, FactSet, S&P CapitalIQ, Yahoo! Finance and Bloomberg to name a select few. STE has hosted over 23 investor conferences which have showcased over 400 companies, attracted over 5000 attendees and have included over 2000 1-on-1 meetings. For more information please visit www.seethruequity.com/conference/.

ETST president, director, and COO, Nickolas S. Tabraue and ETST Public Relations David Demarest, will be attending the conference to share the Company story, confer sector awareness, while enhancing their B2B network.

“I’m truly honored and excited to be attending such an amazing event with other great companies. I feel the SeeThruEquity Conference is the perfect stage for us to share our amazing story, the lives we changed, our growth, and future. We plan to meet key individuals to truly help catapult us to the next level within the market and potentially build key synergies with likeminded companies”, stated Nickolas S. Tabraue and continued with, “we also plan on sharing some very exciting updates and achievement in our Cannabis Therapeutics and Earth Science Pharmaceutical subsidiaries, as well as our strong positive response with our new products launched late last week that has brought many new substantial international and domestic distribution accounts currently in negotiations that will be taking us to new levels. We greatly appreciate our loyal stakeholders support throughout our growth and we look forward sharing many exciting updates mentioned above very soon.”

About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. To find out more information on all our research please visit our website: www.earthsciencetech.com

ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include:
• Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/12/09/794223/0/en/Earth-Science-Tech-Announces-the-Conclusion-of-Phase-1-Trial-with-Former-Professional-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html)

• Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/10/29/781678/0/en/Earth-Science-Tech-Starts-30-day-Trial-Study-with-Former-Professional-Football-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html)

• Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection. (https://globenewswire.com/news-release/2015/10/20/777795/0/en/Earth-Science-Tech-Files-International-PCT-on-its-Hemp-CBD-Cannabidiol-Invention-and-Provisional-Patent-Cannabidiol-Compositions-Including-Mixtures-and-Uses-Thereof-Related-to-Trea.html)

• Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD). (https://globenewswire.com/news-release/2015/10/16/776942/0/en/Earth-Science-Tech-Announces-Case-Studies-to-Begin-With-Former-Pro-Athletes.html)

• DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm)

• DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm)

• Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-test-results-its-product-cbd-cannabidiol-rich-otcqb-etst-1985844.htm)

• Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD(Cannabidiol) Rich Hemp Oil Because of Its Findings with the University of Central Oklahoma and the Effects of CBD on Immune Cells. (http://www.marketwired.com/press-release/earth-science-tech-secures-ground-breaking-second-provisional-patent-its-cbd-cannabidiol-otcqb-etst-1983756.htm)

• Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-preliminary-test-results-on-effects-its-hemp-oil-otcqb-etst-1956064.htm)

• ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells. (http://www.marketwired.com/press-release/etst-college-mathematics-science-university-central-oklahoma-join-forces-joint-effort-otcqb-etst-1949268.htm)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com

The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Cannabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The THREE (3) cannabis cannabinoid-based nutraceutical patents and TWO (2) generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
Dave Demarest
(305)-546-7640

Earth Science Tech, Inc.
Nickolas S. Tabraue, P/D/COO
(305)-615-2118

Source: Earth Science Tech, Inc.

 

Earth Science Tech, Inc. Launches the First Ever Strawberry Orange Blossom CBD Oil, an Organic Chocolate CBD Edible Line, and It’s Pet CBD.



Hollywood, May 18, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis CBD-based (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices and its subsidiary, Cannabis Therapeutics Inc., are proud to announce the launch the first Orange Blossom CBD Oil product in the Hemp CBD Industry along with its new Hemp Pet CBD product and Organic Chocolate line produced as a result of the joint venture with Karmavore Superfoods partnership.

In the ongoing pursuit of ultimate health, wellness, and innovation to be leading Industrial High Grade Hemp CBD brand, Dr. Michel Aube and ETST’s team of scientists have formulated the first High Grade Hemp CBD Strawberry Orange Blossom Oil in the Hemp CBD market as mentioned in April. The oil is based off Earth Science Tech’s Full Spectrum Industrial Cannabidiol (CBD) Hemp Oil mixed with Natural Strawberry Flavoring, Coconut Oil (MCT), and Orange Blossom Honey sourced from Florida. The combination of the natural strawberry and orange blossom honey masks the CBD oil flavor extremely well, having the perfect blend of flavor and sweetness.

“Based on our sample test studies, it’s the best tasting CBD oil available, and we foresee it being a huge hit. Not only does it taste amazing, but the orange blossom honey adds an extra benefit as an allergy inflammation suppressant due to the increase effect of the polyphenol and flavonoid that boosts the effects of the alkaloid in CBD. Moreover it has been shown that the bioavailable polyphenolic constituents of the Citrus sinensis (scientific name of Orange Blossom) can accumulate prevalently at intestinal level where, according to me, it could synergize with CBD to preserve a good digestive health,” stated Dr. Michel Aube, ETST’s CEO & CSO.

ETST is also excited to announce the launch of its new organic raw chocolate line developed through a strategic joint venture partnership with Karmavore Superfoods (announced January 2017). This new product line of superfood-based organic raw chocolate, infused with ETST’s High Grade Hemp CBD, will initially consist of raw chocolate with vanilla roasted almonds, raw chocolate jungle peanut butter cup, and raw chocolate mini jungle peanut butter cups, with additional products in development. The addition of Karmavore’s CBD products will enable ETST to include edibles to its growing line of CBD related products already including oils, powder and veggie caps. Karmavore’s CBD raw chocolate sales have been rapidly growing and have shown to be very popular with tremendous industry excitement and increasing demand.

ETST’s CBD chocolate edibles are specifically formulated by Karmavore Superfoods using ETST’s Full Spectrum Industrial High Grade Hemp CBD Oil, with various other superfood ingredients intentionally selected for their nutritional density, and health and metabolic benefits. They are low in sugar and refined sugar free, preventing sugar rushes and crashes allowing the brain to better process the effects of the CBD and raw chocolate. The combined ingredients not only offer a delicious therapeutic product but, the synergistic combination of healthy fats, antioxidants, and CBD offers an abundance of therapeutic benefits, which have tremendously positive effects on our sense of wellbeing, comfort and calmness. Not only do these products taste amazing, they are also incredibly healthy and extremely effective at delivering CBD throughout the body’s cells.

So how does it work? There is a cannabinoid neurotransmitter called Anandamide found in raw chocolate. Anandamide is a naturally endogenous cannabinoid found in the brain and nervous system which greatly affects our mood and feelings of overall well-being. CBD and Anandamide are keys that fit into cannabinoid receptor sites in mammals. Like a “lock-in-key” system, anandamide in chocolate helps the CBD better penetrate the cell walls making the beneficial effects of CBD more readily available and effective in the body. Raw chocolate’s Anandamide specifically influences cells that affect mood, memory, appetite, pain perception, with similar medicinal benefits as THC.

In even higher concentrations than Anandamide, raw chocolate also contains cannabinoid breakdown inhibitors N-oleolethanolamine (OEA) — a weight gain inhibitor in mice, and the anti-inflammatory molecule N-linoleoylethanolamine (18:3 NAE). These two compounds inhibit the metabolic breakdown of Anandamide and could potentially inhibit the breakdown of other cannabinoids including CBD and THC, causing them to remain in the body longer, allowing smaller doses to be more effective and beneficial. Theobromine, a caffeine-relative found in raw chocolate is a vasodilator and helps deliver nutrients and chemicals into the body’s tissues and may also act as a CBD and Anandamide enhancer, also exaggerating their effects and benefits.

Brian Miller, Karmavore Superfood’s founder & CEO said, “It has been a great pleasure working with ETST since we started almost a year ago. I feel they have the best, most effective CBD oils we’ve tried. Their team has been great to work with and are extremely passionate about what they do. I have been meeting with Dr. Michel Aube and working on some new innovative products and potential new distribution avenues. I very much look forward to continuing to developing our business relationship — and of course making ridiculously healthy and effective CBD edibles more available and accessible.”

Gabriel Aviles, ETST’s Chief Sales Officer confidently and excitedly said, “the excitement and demand for our new Strawberry Orange Blossom and Organic Chocolate Edible Line has been amazing. We have been receiving countless pre-orders, positive results on our new revamped look, and our sales are projected to really take off with all of our new products attracting new accounts and much larger orders.”

Nickolas S. Tabraue, ETST’s President & COO updates the market, “I’m excited to have our new products released after a few setbacks, but it was truly well worth the wait. Our new packaging and design is much cleaner having our band truly stand out in store shelves, and our new flavored CBD Oil, Organic Chocolate CBD line, and Pet CBD have been completed properly offering the best quality to our loyal and much appreciated customers/accounts. We strive to be innovative, offering only the best quality, delivery, and flavored CBD, as well as evolving as company by offering a true branded experience. We still look to be on track with our patent pending CBD compounds and we plan on updating our stakeholders as soon as we finalize a very exciting opportunity that has risen.”

ETST continuously plans on updating its shareholders on the above mentioned studies and new products as further progress and development occurs.

About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. To find out more information on all our research please visit our website: www.earthsciencetech.com

ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include:
• Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/12/09/794223/0/en/Earth-Science-Tech-Announces-the-Conclusion-of-Phase-1-Trial-with-Former-Professional-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html)

• Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/10/29/781678/0/en/Earth-Science-Tech-Starts-30-day-Trial-Study-with-Former-Professional-Football-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html)

• Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection. (https://globenewswire.com/news-release/2015/10/20/777795/0/en/Earth-Science-Tech-Files-International-PCT-on-its-Hemp-CBD-Cannabidiol-Invention-and-Provisional-Patent-Cannabidiol-Compositions-Including-Mixtures-and-Uses-Thereof-Related-to-Trea.html)

• Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD). (https://globenewswire.com/news-release/2015/10/16/776942/0/en/Earth-Science-Tech-Announces-Case-Studies-to-Begin-With-Former-Pro-Athletes.html)

• DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm)

• DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm)

• Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-test-results-its-product-cbd-cannabidiol-rich-otcqb-etst-1985844.htm)

• Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD(Cannabidiol) Rich Hemp Oil Because of Its Findings with the University of Central Oklahoma and the Effects of CBD on Immune Cells. (http://www.marketwired.com/press-release/earth-science-tech-secures-ground-breaking-second-provisional-patent-its-cbd-cannabidiol-otcqb-etst-1983756.htm)

• Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-preliminary-test-results-on-effects-its-hemp-oil-otcqb-etst-1956064.htm)

• ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells. (http://www.marketwired.com/press-release/etst-college-mathematics-science-university-central-oklahoma-join-forces-joint-effort-otcqb-etst-1949268.htm)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com

The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
Dave Demarest
(305)-546-7640


Earth Science Tech, Inc.
Nickolas S. Tabraue, P/D/COO
(305)-615-2118

Source: Earth Science Tech, Inc.

 

 

Earth Science Tech, Inc. Shares Achievements & Updates on it’s Cannabis CBD-Based Nutraceutical Patent Compounding



Hollywood, May 2, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis CBD based (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices and it’s subsidiary Cannabis Therapeutics Inc. are proud to announce the achievements and updates on its CBD-based nutraceutical patent compound.

Dr. Aube Earth Science Tech’s CEO & CSO, meets with Dr. Domenico and his chemical engineer every Tuesday, at Smart Medicines and have been working on three formulas. The formulas are in a solid, liquid, and semi solid form. Out of all three forms ETST’s science team sees the semi solid formula’s potential as a huge success. The final product looks similar to regular mustard, but it’s a very special condiment that keeps all properties of full spectrum hemp oil.

Both the color and taste of the formula can be changed with ETST’s U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST’s U.S. Provisional Application No. 62/102,538, filed January 12, 2015 along with other food coloring and natural flavors. It’s formulated with high industrial hemp CBD oil (30%) and CBD concentration, and can be packaged in a tube to be consumed directly as it is (half a tea spoon 3 times/day) as a nutraceutical product.

The product can keep the same texture and inert ingredients as the nutraceutical product but, with modulations of the amount of hemp oil (between 5% and 30%), and can be sold as a functional food, a condiment to flavor everyday food, as well as a dietary supplement.

For distinction between functional foods, nutraceuticals, and dietary supplements you can read this paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750935/

Text from the paper:

“Thus, nutraceuticals (as per the proposed definition) differ from dietary supplements in the following aspects: Nutraceuticals must not only supplement the diet but should also aid in the prevention and/or treatment of disease and/or disorder.  CONCLUSION When a functional food aids in the prevention and/or treatment of disease (s) and/or disorder(s) (except anemia), it is called a nutraceutical. The proposed definition can help form distinction between functional foods, nutraceuticals, and dietary supplements. ”

There is no rule for the nutraceutical products. We can claim that our product is a nutraceutical and ongoing research.

In conclusion, we have the first nutraceutical formula with ETST’s U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST’s U.S. Provisional Application No. 62/102,538, filed January 12, 2015 nearly ready to apply to get a natural product number (NPN is mandatory to get license to sale in Canada) and FDA approval (Federal Food, Drug, and Cosmetic Act).

Dr. Aube stated, “I’m very proud and happy with our Science team achieving such great formulas and reaching closer to finalizing our three planned compounds. We look to be on track from our March 6, 2017 announcement and look forward on sharing more updates as we continue progressing. We plan on sharing our first video on our Cannabis Therapeutics along with many photos to share with our investors our profession very soon as well as finalizing Earth Science Pharmaceutical website that looks to be finalized within May.”

Nickolas S. Tabraue ETST’s President & COO updates the market, “We are still on track to release our highly anticipated, world-first High Grade Hemp CBD Strawberry Orange Blossom, Pet CBD, and our new edible line in mid-May as mentioned on April 20, 2017. Bottling and packaging look to commence during the first week of May and we plan on showing images on our new products and packaging very soon. Our Chief Sales Officer, Gabriel Aviles, has been receiving endless pre-order requests on our new line and we are on pace to have a record breaking month. Aside from our new products, packaging, and positive revenue forecast, we are looking to finalize a few major breakthroughs I will be excited to share when we have something more concrete in place. We greatly appreciate our loyal stakeholders’ support and look forward on showing the public where all the support has taken us, and what it has helped us build.”

ETST continuously plans on updating its shareholders on the above mentioned studies and new products as further progress and development occurs.

About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. To find out more information on all our research please visit our website: www.earthsciencetech.com

ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based

Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include:

• Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/ 2015/12/09/794223/0/en/Earth-Science-Tech-Announces-theConclusion-of-Phase-1-Trial-with-Former-Professional-Athletes-UsingETST-High-Grade-Hemp-CBD-Cannabidiol.html)

• Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/10/29/781678/0/en/ Earth-Science-Tech-Starts-30-day-Trial-Study-with-Former-ProfessionalFootball-Athletes-Using-ETST-High-Grade-Hemp-CBDCannabidiol.html)

• Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection. (https:// globenewswire.com/news-release/2015/10/20/777795/0/en/EarthScience-Tech-Files-International-PCT-on-its-Hemp-CBD-CannabidiolInvention-and-Provisional-Patent-Cannabidiol-Compositions-IncludingMixtures-and-Uses-Thereof-Related-to-Trea.html)

• Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD). (https://globenewswire.com/news-release/ 2015/10/16/776942/0/en/Earth-Science-Tech-Announces-Case-Studiesto-Begin-With-Former-Pro-Athletes.html)

• DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant. (http://
www.marketwired.com/press-release/dv-biologics-leading-biologicalcompany-reports-earth-science-tech-etst-high-grade-hemp-otcqbetst-2032087.htm)

• DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro. (http:// www.marketwired.com/press-release/dv-biologics-leading-biologicalcompany-reports-earth-science-tech-etst-high-grade-hemp-otcqbetst-2032087.htm)

• Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function.
(http://www.marketwired.com/pressrelease/earth-science-tech-announces-positive-test-results-its-productcbd-cannabidiol-rich-otcqb-etst-1985844.htm)

• Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD(Cannabidiol) Rich Hemp Oil Because of Its Findings with the University of Central Oklahoma and the Effects of CBD on Immune Cells. (http://www.marketwired.com/press-release/earth-science-tech-securesground-breaking-second-provisional-patent-its-cbd-cannabidiol-otcqbetst-1983756.htm) 

• Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. (http://www.marketwired.com/pressrelease/earth-science-tech-announces-positive-preliminary-test-resultson-effects-its-hemp-oil-otcqb-etst-1956064.htm)

• ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and AntiTumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells. (http://www.marketwired.com/press-release/ etst-college-mathematics-science-university-central-oklahoma-joinforces-joint-effort-otcqb-etst-1949268.htm)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com

The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com 

Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations   Dave Demarest  (305)-546-7640  

Earth Science Tech, Inc.   Nickolas S. Tabraue, P/D/COO   (305)-615-2118

Source: Earth Science Tech, Inc

 

ETST Launches Cannabis Therapeutics Website, Shares Updates on their CBD-Based Nutraceutical Patents, & Hints on New Products Launching May 2017



Hollywood, April 20, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices, and its two subsidiaries Earth Science Pharmaceutical Inc. and Cannabis Therapeutics Inc. are proud to announce the completion and launch of their informative Cannabis Therapeutics website, and in addition to providing updates on the development of the cannabinoid-based Patent nutraceutical products.

We have successfully launched the website, http://cannabisthera.com, and will continue to update with new content regularly, in order to show transparency, provide the most up-to-date product information and keep investors informed. This will include a corporate blog with more frequent updates on the company’s work and monthly videos with Dr. Aube and his team.

Over the past several weeks, executives from Earth Science Tech have been meeting with the R&D team from Smart Medicine. In the last weekly meeting, several milestones were discussed and progress has been made. Formulations for the company’s three varieties of High Grade Industrial Hemp CBD Oil nutraceutical formulas have been completed. The company is moving forward quickly on its International Application for Provisional Patents, and this progress was discussed. Formulations leveraging ETST’s U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST’s U.S. Provisional Application No. 62/102,538, filed January 12, 2015 to oxidative stress for athletes, individuals with chronic inflammation, and women during peri-menopause and menopause are being actively developed as part of the new Women’s Health initiatives the company recently announced, (https://globenewswire.com/news-release/2017/04/11/958716/0/en/Earth-Science-Tech-Inc-Targets-Breast-Cancer-and-Other-Women-s-Health-Issues-in-New-Cannabis-CBD-Based-Pharmaceutical-Drug-Development-Initiatives.html). The resulting formulas are expected to be beneficial for Parkinson’s, Alzheimer, and cancer patients as well. The first formula is expected to be finished and ready for testing in mid 2017.

“The applications of nutraceuticals that leverage ETST’s U.S. Provisional Application N. 62/061,577 and ETST’s U.S. Provisional Application No. 62/102,538 to prevent oxidative stress are near endless,” said CEO & CSO Dr. Michel Aube, “We see a tremendous market that goes far beyond the initial scope we were pursuing, and things are moving very quickly. We are quite optimistic with the results we have seen thus far.”

The company is expecting to have its High Grade Industrial Hemp CBD Patent pending formulas ready to be sold in stores by the end of 2017.

“After speaking with Michel and hearing the optimism coming from the development work being completed, we’re expanding our horizons,” said CSO Gabriel Aviles, “We are expecting to be able to reach a great deal of new customers with our niche provisional patent products. Q3 and Q4 will be huge for us in terms of gaining a foothold on these markets.”

“In addition to all of the hard work our scientific teams are doing, we are still on track to launch our Pet CBD products and revamped packaging we mentioned in March (https://globenewswire.com/news-release/2017/03/30/947031/0/en/Earth-Science-Tech-Inc-Expands-Marketing-Campaign-to-MassRoots-OTC-MSRT-Natural-Awakenings-Magazine-and-Enhances-Product-Packaging.html), as well a new flavored High Grade Hemp CBD Oil with added therapeutic properties (new to the market) and therapeutic edibles as early as this May. We plan on sharing these new exciting innovative products as we get closer to launching. Our team has been working hard on making sure to be the forefront in the CBD industry and making sure we can continue helping and positively changing individual’s lives.” concluded President & COO Nickolas Tabraue.

ETST continuously plans on updating its shareholders on the above mentioned studies and new products as further progress and development occurs.

About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. To find out more information on all our research please visit our website: www.earthsciencetech.com

ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include:
• Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/12/09/794223/0/en/Earth-Science-Tech-Announces-the-Conclusion-of-Phase-1-Trial-with-Former-Professional-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html)

• Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/10/29/781678/0/en/Earth-Science-Tech-Starts-30-day-Trial-Study-with-Former-Professional-Football-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html)

• Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection. (https://globenewswire.com/news-release/2015/10/20/777795/0/en/Earth-Science-Tech-Files-International-PCT-on-its-Hemp-CBD-Cannabidiol-Invention-and-Provisional-Patent-Cannabidiol-Compositions-Including-Mixtures-and-Uses-Thereof-Related-to-Trea.html)

• Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD). (https://globenewswire.com/news-release/2015/10/16/776942/0/en/Earth-Science-Tech-Announces-Case-Studies-to-Begin-With-Former-Pro-Athletes.html)

• DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm)

• DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm)

• Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-test-results-its-product-cbd-cannabidiol-rich-otcqb-etst-1985844.htm)

• Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD(Cannabidiol) Rich Hemp Oil Because of Its Findings with the University of Central Oklahoma and the Effects of CBD on Immune Cells. (http://www.marketwired.com/press-release/earth-science-tech-secures-ground-breaking-second-provisional-patent-its-cbd-cannabidiol-otcqb-etst-1983756.htm)

• Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-preliminary-test-results-on-effects-its-hemp-oil-otcqb-etst-1956064.htm)

• ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells. (http://www.marketwired.com/press-release/etst-college-mathematics-science-university-central-oklahoma-join-forces-joint-effort-otcqb-etst-1949268.htm)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com

The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
Dave Demarest
(305)-546-7640

Earth Science Tech, Inc.
Nickolas S. Tabraue, P/D/COO
(305)-615-2118

Source: Earth Science Tech, Inc.

 

Earth Science Tech, Inc. Targets Breast Cancer and Other Women's Health Issues in New Cannabis CBD-Based Pharmaceutical Drug Development Initiatives



Hollywood, April 11, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, and its two subsidiaries Earth Science Pharmaceutical Inc. and Cannabis Therapeutics Inc., are proud to announce that they will be targeting breast cancer and other women’s health issues with their latest cannabis CBD-based (Indutrial Hemp) pharmaceutical drug development and research initiatives.

At the monthly Scientific Advisory Board development meeting on April 4th, attended by Dr. Chandra Panchal, Dr. Domenico Fuoco, Dr. Moutih Rafei, CEO/CSO Dr. Michel Aubé, and representatives of Smart Medicine, Inc., the group decided that their drug development initiative should target breast cancer and other women’s health issues. Cannabis-based treatments have proven to be tremendously effective in treating various forms of cancer, including breast cancer, and Dr. Michel Aubé has years of expertise in this specific niche. 

With the new direction established, the company has re-focused on several initiatives that will benefit the health of women worldwide. Around the world, women suffer from lack of access to healthcare, both for economic and political reasons, and an inability to take charge of their own health and healthcare. ETST is committed to developing products and services that give women easier access and more control over specific health issues that impact their lives.

The company is launching an in-depth study of cannabidiol’s known, unique anti-proliferative effect on breast cancer cells. CEO and Chief Scientific Officer Dr. Michel Aubé will leverage his expertise in this subject, having conducted research on deciphering the mechanism of action of organochlorine on breast cancer cells in his doctorate studies, to lead the group through the drug development pipeline. His previous work resulted in this scientific paper regarding breast cancer: https://www.ncbi.nlm.nih.gov/pubmed/18275596

ETST’s goal is to bring generic pharmaceutical breast cancer and chemo-prevention drugs to market, making them affordable and available to women around the globe.

Several of the company’s immediate drug development projects will target breast and ovarian cancers, allowing that important work to benefit from an established in vitro and in vivo experimental infrastructure. Dr. Moutih and Dr. Aube will plan all in vitro and in vivo experiments and Dr. Rafei’s will supervise all experimental procedures.

The company’s relationships with Dr. Rafei’s and Smart Medicine will allow it to apply for public and private research grants to engage in R&D to:

Prove that Cannabis Therapeutics' Inc. Cannabinoid-improved generic drugs are more efficient - with less active molecules - than existing drugs, and therefore have fewer and less severe side effects on patients, particularly cancer patients.
Discover new applications for existing drugs.
Test the effects of cannabinoids on the human immune system should significant results come from the first round of research.
Create synthetic cannabinoids
Additionally, ETST is working on building a strategic partnership with Connexions Commerciales Internationales C.T. Inc., a company focused on hormonal replacement therapies. As previously announced, https://globenewswire.com/news-release/2017/03/27/945536/0/en/Earth-Science-Tech-Inc-Announces-Timeline-Projection-for-its-MSN-2-Medical-Device-and-Partnership-Negotiations-for-its-Cannabis-CBD-Based-Generic-Drugs-Medical-Device-Distribution.html. Many of their generic drugs will also be targeted to women health issues.

ETST’s other subsidiary, Earth Science Pharmaceutical Inc., is launching its first product, a medical device that will empower women to take an active role to protect themselves from the long-term medical problems caused by the Sexually Transmitted Infections chlamydia and gonorrhea.

ETST continuously plans on updating its shareholders on the above mentioned studies as further progress and development occurs.

About Earth Science Tech, Inc. (ETST): Earth Science Tech is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals, Pharmaceuticals, and Medical devises for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. Visit corporate website at www.earthsciencetech.com

ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include:

Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/12/09/794223/0/en/Earth-Science-Tech-Announces-the-Conclusion-of-Phase-1-Trial-with-Former-Professional-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html)
Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/10/29/781678/0/en/Earth-Science-Tech-Starts-30-day-Trial-Study-with-Former-Professional-Football-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html)
Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection. (https://globenewswire.com/news-release/2015/10/20/777795/0/en/Earth-Science-Tech-Files-International-PCT-on-its-Hemp-CBD-Cannabidiol-Invention-and-Provisional-Patent-Cannabidiol-Compositions-Including-Mixtures-and-Uses-Thereof-Related-to-Trea.html)
Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD). (https://globenewswire.com/news-release/2015/10/16/776942/0/en/Earth-Science-Tech-Announces-Case-Studies-to-Begin-With-Former-Pro-Athletes.html)
DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm)
DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm)
Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-test-results-its-product-cbd-cannabidiol-rich-otcqb-etst-1985844.htm)
Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD(Cannabidiol) Rich Hemp Oil Because of Its Findings with the University of Central Oklahoma and the Effects of CBD on Immune Cells. (http://www.marketwired.com/press-release/earth-science-tech-secures-ground-breaking-second-provisional-patent-its-cbd-cannabidiol-otcqb-etst-1983756.htm)
Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-preliminary-test-results-on-effects-its-hemp-oil-otcqb-etst-1956064.htm)
ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells. (http://www.marketwired.com/press-release/etst-college-mathematics-science-university-central-oklahoma-join-forces-joint-effort-otcqb-etst-1949268.htm)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com

The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
Dave Demarest
(305)-546-7640


Earth Science Tech, Inc.
Nickolas S. Tabraue, P/D/COO
(305)-615-2118

Source: Earth Science Tech, Inc.

 

Earth Science Tech, Inc. Expands Marketing Campaign to MassRoots (OTC: MSRT), Natural Awakenings Magazine, and Enhances Product Packaging



Hollywood, March 30, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, has been working closely with different advertising outlets to continue increasing demand for Earth Science Tech’s products across the country.

April's Natural Awakening Half Page Ad

In April, Earth Science Tech will be featured in a half-page ad in Natural Awakenings magazine, a publishing outlet that reaches 4+ million consumers across the entire U.S., and several other countries. Additionally, the company’s advertising statistics show that 80% of their readers make purchases based on advertisements they see in Natural Awakenings. (http://www.naturalawakeningsmag.com)

“Natural Awakenings has historically had very high ROI opportunities for its advertisers,” said CSO and Director, Gabriel Aviles, “They reach a demographic that has disposable income, is passionate about health, and seeks natural alternatives. This is a great market for us to tell our story to.”

Also in April, the company will be working with MassRoots (OTC: MSRT) to build demand for our new product lines launching within Q2 2017. MassRoots is one of the largest web portals within the cannabis industry, and over 1,000,000 cannabis enthusiasts are registered with the platform. This is one of the best niche advertising locations for a cannabis-based product to reach. (https://massroots.com)

“MassRoots is hands down one of the best platforms to launch a cannabis-based (Indsutrial Hemp) product from,” said CMO Sergio Castillo, “We can reach nearly a million registered users, gain major brand recognition, and build early demand for our innovative new products. This is a great opportunity for maximum brand exposure.”

In order for our current and new product lines to appeal to a wider range of customers, the packaging is being revamped and will now feature UV spotting on the front/face of the boxes. The relaxing amber bottles will now reflect the company’s blue and white branding with its new packaging.

“Our new packaging's sleek, modern, and attractive appearance will capture new and existing consumers differentiating our brand from competitors,” said President, Director, and COO, Nickolas Tabraue, “We’ve stayed true to our branding, but our new look stands to set us apart from the competition on the shelves. We are very happy with how our packaging is turning out and we are looking forward to very promosing Q2 2017 launch.”

ETST will continuously update its shareholders on the new packaging, new products be launched during Q2, joint ventures being finalized, and other developments as further progress occurs.

About Earth Science Tech, Inc. (ETST): Earth Science Tech is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals, Pharmaceuticals, and Medical devises for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. Visit corporate website at www.earthsciencetech.com

ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include:

Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/12/09/794223/0/en/Earth-Science-Tech-Announces-the-Conclusion-of-Phase-1-Trial-with-Former-Professional-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html)
Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/10/29/781678/0/en/Earth-Science-Tech-Starts-30-day-Trial-Study-with-Former-Professional-Football-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html
Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection. (https://globenewswire.com/news-release/2015/10/20/777795/0/en/Earth-Science-Tech-Files-International-PCT-on-its-Hemp-CBD-Cannabidiol-Invention-and-Provisional-Patent-Cannabidiol-Compositions-Including-Mixtures-and-Uses-Thereof-Related-to-Trea.html)
Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD). (https://globenewswire.com/news-release/2015/10/16/776942/0/en/Earth-Science-Tech-Announces-Case-Studies-to-Begin-With-Former-Pro-Athletes.html)
DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm)
DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm)
Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-test-results-its-product-cbd-cannabidiol-rich-otcqb-etst-1985844.htm)
Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD(Cannabidiol) Rich Hemp Oil Because of Its Findings with the University of Central Oklahoma and the Effects of CBD on Immune Cells. (http://www.marketwired.com/press-release/earth-science-tech-secures-ground-breaking-second-provisional-patent-its-cbd-cannabidiol-otcqb-etst-1983756.htm)
Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-preliminary-test-results-on-effects-its-hemp-oil-otcqb-etst-1956064.htm)
ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells. (http://www.marketwired.com/press-release/etst-college-mathematics-science-university-central-oklahoma-join-forces-joint-effort-otcqb-etst-1949268.htm)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com

The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
Dave Demarest
(305)-546-7640


Earth Science Tech, Inc.
Nickolas S. Tabraue, P/D/COO
(305)-615-2118

Source: Earth Science Tech, Inc.

 

Earth Science Tech, Inc. Announces Timeline Projection for its MSN-2 Medical Device, and Partnership Negotiations for its Cannabis CBD-Based Generic Drugs & Medical Device Distribution



Hollywood, March 27, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, and its two subsidiaries - Earth Science Pharmaceutical Inc. and Cannabis Therapeutics inc. - are proud to announce the projected timeline for the delivery of its MSN-2 medical device; the negotiation of a strategic partnership with Connexions Commerciales Internationales ct, Inc.; and the beginning of negotiations with partners in Africa and Japan.

The MSN-2 medical device was announced in November 2016, (https://globenewswire.com/news-release/2016/11/21/891699/0/en/ETST-Announces-60-Patient-Clinical-Prelaunch-Study-for-its-MSN-2-Medical-Device-for-the-Diagnosis-of-Chlamydia-Gonorrhea-ETST-Elects-Dr-Michel-Aubé-as-New-CEO-CSO-and-Nickolas-Tabr.html). The above mentioned medical device can be used by women to extract a cell sample from herself, which then is shipped to a proprietary lab for analysis of sexually transmitted infections. Our device is proven to sample for chlamydia and is currently undergoing testing to certify the device for gonorrhea sampling.

ETST will inaugurate the manufacturing facility for the MSN-2 medical device within Q2 2017, and the initial product release for detecting Chlamydia only may begin as soon as Q3 2017. The MSN-2 will be marketed only overseas during the beginning. The FDA and Health Canada approvals required to market a Class II medical device in Canada and the USA require the factory to be ISO-13485 accredited, which will take more time, estimating within 12 to 18 months.

The name and branding of the MSN-2 and dedicated e-commerce website will be ready within Q4 2017. The clinical study to detect gonorrhea in the same sample provided by the MSN-2 should be completed within Q4 2017, and by Q1 2018 the service will test for both diseases in the one sample taken by MSN-2.

The new anticipated partnership with Connexions Commerciales Internationales ct, Inc., (https://cancompany.org/co/connexions-commerciales-internationales-c-t-inc) will be an important partner in rolling out ETST’s generic drugs and medical device. The first phase of the rollout will be in Africa, with phase two in Russia later on. To ensure quality manufacturing of the Earth Science Pharmaceutical’s & Cannabis Therapeutic’s products overseas in the facilities of Connexions Commerciales Internationales ct Inc., a strategic partnership between ETST, Smart Medicine, and Connexions Commerciales Internationales ct Inc. is expected to be signed within the next 30 days. This joint venture will focus on growing the ETST portfolio of generic drugs, having a competitive pricing for the industrial production and to put forward on the market and finding avenues to repurpose for both company’s existing generic drugs.

Preventing the spread of STIs is of major concern for ETST, particularly in Africa and in Japan where the company will roll out MSN-2. The goal is to give women more Personal control over their own heath. Despite all the progress in science and medicine, the speed of diagnosis is not sufficiently quick to get patients to treatment before preventable consequences become unpreventable. ETST is working with gynecologists and business people who share the same goal - to improve the health of women as a core value of the business. To that end, ETST is currently in discussions with doctors from a Japanese firm which owns 74 hospitals and more than 40 private clinics, that will help introduce the MSN-2 medical device in Japan and parts of Africa.

ETST will continuously update our shareholders on it’s MSN-2 medical device and other developments as further progress occurs.


About Earth Science Tech, Inc. (ETST): Earth Science Tech is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals, Pharmaceuticals, and Medical devises for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. Visit corporate website at www.earthsciencetech.com

ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include:
• Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/12/09/794223/0/en/Earth-Science-Tech-Announces-the-Conclusion-of-Phase-1-Trial-with-Former-Professional-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html)

• Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol). (https://globenewswire.com/news-release/2015/10/29/781678/0/en/Earth-Science-Tech-Starts-30-day-Trial-Study-with-Former-Professional-Football-Athletes-Using-ETST-High-Grade-Hemp-CBD-Cannabidiol.html)

• Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection. (https://globenewswire.com/news-release/2015/10/20/777795/0/en/Earth-Science-Tech-Files-International-PCT-on-its-Hemp-CBD-Cannabidiol-Invention-and-Provisional-Patent-Cannabidiol-Compositions-Including-Mixtures-and-Uses-Thereof-Related-to-Trea.html)

• Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD). (https://globenewswire.com/news-release/2015/10/16/776942/0/en/Earth-Science-Tech-Announces-Case-Studies-to-Begin-With-Former-Pro-Athletes.html)

• DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm)

• DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro. (http://www.marketwired.com/press-release/dv-biologics-leading-biological-company-reports-earth-science-tech-etst-high-grade-hemp-otcqb-etst-2032087.htm)

• Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-test-results-its-product-cbd-cannabidiol-rich-otcqb-etst-1985844.htm)

• Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD(Cannabidiol) Rich Hemp Oil Because of Its Findings with the University of Central Oklahoma and the Effects of CBD on Immune Cells. (http://www.marketwired.com/press-release/earth-science-tech-secures-ground-breaking-second-provisional-patent-its-cbd-cannabidiol-otcqb-etst-1983756.htm)

• Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. (http://www.marketwired.com/press-release/earth-science-tech-announces-positive-preliminary-test-results-on-effects-its-hemp-oil-otcqb-etst-1956064.htm)

• ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells. (http://www.marketwired.com/press-release/etst-college-mathematics-science-university-central-oklahoma-join-forces-joint-effort-otcqb-etst-1949268.htm)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com

The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
Dave Demarest
(305)-546-7640


Earth Science Tech, Inc.
Nickolas S. Tabraue, P/D/COO
(305)-615-2118

Source: Earth Science Tech, Inc.

 

ETST Announces Recruitment of Key Individuals for its Two Subsidiaries and the Leasing of a Manufacturing Facility to Produce its MSN-2 Medical Device



Hollywood, March 14, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices is proud to announce its subsidiaries Cannabis Therapeutic, Inc. and Earth Science Pharmaceutical, Inc. the nomination of Kim FosterCunningham to the post of Project Manager for the MSN-2 medical device project; and Denis Babin of SDB Import/Export, Inc. as international marketing consultant for Cannabis Therapeutics and Earth Science Pharmaceutical products.

Ms. Foster-Cunningham’s immediate focus is preparatory phase of the pre-market clinical trial of the MSN-2 medical device. The MSN-2 device is a revolutionary medical instrument for the detection and diagnosis of Chlamydia and Gonorrhea, from previous announcement, (ETST Announces 60-Patient Clinical Prelaunch Study for its MSN-2 Medical Device for the Diagnosis of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aubé as New CEO & CSO, and Nickolas Tabraue as President.)

Ms. Foster-Cunningham, whom holds a degree in sales and marketing, is recognized for her expertise in business networking and her solid business expertise. She is a soughtafter speaker throughout the USA and Canada, delivering conferences on her proactive approach to general health and self-care. Passionate about individual sports, she is a half marathon runner and a triathlete. Always enthusiastic about transmitting her passion for health and business development, this project is “her new baby”.

Based on her experience and success in building and managing teams, developing structures and business models, and driving long term projects; Earth Science Pharmaceutical is confident that she embodies all the assets the company needs to make the project a success.

Mr. Babin brings expertise and an excellent record of success in national and International business development. His personal list of contacts – people that he knows and can call and talk to directly - boasts ministers of finance, ministers of health, and owners of laboratories and pharmacies. Mr. Babin is also an expert in electronics, and has experience in employee and staff management.

“This new partnership is very exciting for me because it lines up with my network of contacts in Morocco, Dubai, and Japan. These market leaders are ready to work with me to bring the MSN-2 medical device to their regions.” Babin explained. “My network
includes more than 300 pharmacies plus three important laboratories in Casablanca, Rabat, and Tangier. Many people are aware of the coming MSN-2 device and they can’t wait for it to become on the market for women to use.”

Initially, the MSN-2 medical device will be distributed overseas in drugstores and via the internet. Distribution in North and South American countries will commence when all necessary regulatory issues have been settled.

The company would also like to applaud the fact that Mr. Babin has been instrumental in Earth Science Pharmaceutical’s leasing of a manufacturing facility, which will also house the development team starting in Q2. The new facility is located 15 minutes from the Port of Montreal and 30 minutes from Pierre Eliot Trudeau airport. At the junction of several highways, the facility is ideal for shipping and receiving, and has the space needed to house a production process that will meet the ISO-13485 accreditation standard for the production of medical devices. Most of the needed materials are already in place for the initial setup, and the building gives the company space to grow as it develops more divisions and more specialized projects.

Dr. Michel Aube, ETST’s CEO & CSO commented, “By having Ms. Foster-Cunningham focusing on the preparatory phase of the pre-market clinical trial of the MSN-2 medical device, and leveraging Mr. Babin’s connections and expertise with SDB Mondial Import/ Export to distribute our medical devices, patent CBD formulas, and cannabis CBD-based pharmaceutical generic drugs internally, Earth Science Tech is positioning itself to be a massive global leader in overall health & wellness industry.”

ETST will continuously update our shareholders on it’s MSN-2 medical device and other developments as further progress occurs. ! About Earth Science Tech, Inc. (ETST): Earth Science Tech is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals, Pharmaceuticals, and Medical devises for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. Visit corporate website at www.earthsciencetech.com

ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All NaturalOrganic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/ CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug
Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com ! The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com ! Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
Dave Demarest
(305)-546-7640
Earth Science Tech, Inc.
Nickolas S. Tabraue, P/D/COO
(305)-615-2118

Source: Earth Science Tech, Inc.

 

Earth Science Tech, Inc. Announces New Cannabis CBD-Based Sports Supplement with Forzagen, Karmavore Superfoods Sales Success, and Company Updates



Hollywood, March 09, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, is pleased to announce it has formulated a new Cannabis CBD-based pre-workout sports supplement with Forzagen. Additionally, the company’s joint venture with Karmavore Superfoods is off to a good start, and their chocolates (infused with ETST CBD) are selling well.

The company recently announced a joint venture with Nutrition Specialties and Forzagen, (Earth Science Tech, Enters Multi-Billion Dollar Sports Supplement Industry via Joint Venture with Nutrition Specialties and Forzagen) where Earth Science Tech and Forzagen will formulate new CBD-based sports products. Earth Science Tech will help develop the market in the United States while Forzagen will develop the market in Mexico and other international accounts. Earth Science Tech, together with Forzagen, have formulated a full-spectrum CBD-based pre-workout supplement called Black Demon 2.0. The supplement was formulated for serious athletes, and is incredibly potent. Forzagen and Earth Science Tech will be splitting both the costs and revenues of Black Demon 2.0, and it is currently in the label design phase. It is expected to be bottled and start selling within Q2 or Q3 of 2017.

“We have seen great success with our non-CBD products in the past, but we are expecting even greater success with Black Demon 2.0,” said Forzagen owner, Jose Bucay, “We’ve already have competitive athletes testing the supplement, and have nothing but positive feedback in regards to Black Demon 2.0. We think we’ve got a true hit in the making.”

The company recently announced a joint venture with Karmavore Superfoods, (Earth Science Tech, Inc. (OTC: ETST) Finalizes Joint Venture with Karmavore Superfoods and Signs New CMO, Sergio Castillo) where Earth Science Tech would help develop sales channels for Karmavore’s products, while Karmavore would source its cannabis CBD-based ingredients from Earth Science Tech. The initial sales of Kamavore Superfood’s CBD infused chocolates under this joint venture have been selling rapidly with great excitement and feedback from store owners and customers. Karmavore Superfoods recently expanded their CBD organic raw chocolate offering with the launch of a new line of CBD peanut butter cups. Initial feedback has been overwhelmingly positive. With nothing like them in the market they are sure to be a game changer in the CBD edibles industry. (http://www.karmavoresuperfoods.com/product-category/hemp-cbd/).

“We’ve never seen our products move so quickly,” said Brian Miller, owner of Karmavore, “It’s amazing how our specially formulated raw chocolate works with ETST’s CBD oil. We’ve truly created a whole new chocolate experience — and the feedback we’ve been getting from our customers confirms not just how great the products taste, but more importantly how the CBD chocolate makes them feel. It’s a great sign that after only a few weeks of signing this joint venture we’re already seeing incredible growth. We are looking forward to a long and fruitful relationship with Earth Science Tech.”

The company is also hard at work on a new therapeutic, flavored CBD product that will provide consumers with another great tasting CBD oil, while still being all natural having the flavoring provide additional therapeutic benefits. This new product is currently being mixed, and a release plan is expected to be executed before Q3 of 2017.

“We are in a very unique position here, as our company is becoming well-known for its quality and formulation capabilities. We’re seeing more and more opportunities coming our way to work with established companies like Karmavore and Forzagen to build mutually beneficial relationships that build sales for both parties,” said CSO and Director, Gabriel Aviles, “This is giving us the opportunity to develop sales channels in places that would have been much harder to reach alone, and it’s greatly ramping up our operations. We are entertaining offers from international distributors and new potential joint venture partners as we speak.”

“With nothing but positive results coming from all of our recent partnerships, we feel we’re on a great path right now,” said President, Director, and COO, Nickolas Tabraue, “Unfortunately, we are experiencing delays in getting our pet CBD product packaging finished, but we still expect to be ready to launch by Q2 2017. We apologize for the delay, but we are hard at work on expanding our product lines, partnerships, and sales channels to increase shareholder value.”

ETST will continuously update our shareholders on the above mentioned product developments, sales, and new joint ventures as further progress occurs.

About Earth Science Tech, Inc. (ETST): Earth Science Tech (www.earthsciencetech.com) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals and Cosmeceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
Dave Demarest
(305)-546-7640

Earth Science Tech, Inc.
Nickolas S. Tabraue, P/D/COO
(305)-615-2118

Source: Earth Science Tech, Inc.

 

ETST & Cannabis Therapeutics Inc. Announce its Cannabis Cannabinoid-Based Nutraceutical Patent & Generic Pharmaceutical Drug Timeline & Update.



Hollywood, March 06, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices based company is proud to announce that its wholly owned subsidiary Cannabis Therapeutics timeline for its cannabis cannabinoid based nutraceutical patent and generic pharmaceutical drug completion.

At a meeting with the company's Advisory Board on Tuesday, February 28th at Le Centre Québecois d'Innovation en Biotechnologie (CQIB) in Laval, Québec; the scientists concluded that the improved CBD Hemp Oil food supplement was ready to move to prototyping, and then to be fast tracked to commercialization. In addition, two cannabinoid-based generic pharmaceutical drugs will be ready for premarket clinical trials related to drug bioavailability by Q3 2017. Depending on the time needed to properly conduct the clinical trials, both of the pharmaceutical drugs looks to be completed by the end of 2017 or beginning of 2018.

The first or these two generic drugs, an anti-breast cancer drug, is an important advance for the company as breast cancer affects more women worldwide than any other cancer. The components of the anti-breast cancer drug that Cannabis Therapeutics is bringing to market are contained in the World Health Organization’s current Model List of Essential Medicines (2015). The WHO Model Complementary List indicates the essential medicines needed to treat priority diseases, such as breast cancer, by any healthcare system.

Other items to note from the meeting:
 

ETST continuously plans on updating its shareholders on the above mentioned studies as further progress and development occurs as well as highly anticipated news we plan to soon unfold.


About Earth Science Tech, Inc. (ETST): Earth Science Tech (www.earthsciencetech.com) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals and Cosmeceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All NaturalOrganic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hempbased Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new nonpsychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forwardlooking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Dave Demarest (305)-546-7640

Earth Science Tech, Inc. Nickolas S. Tabraue, P/D/COO (305)-615-2118

Source: Earth Science Tech, Inc.


 

Earth Science Tech Inc. and Cannabis Therapeutics Inc. to hold High-Level R&D Strategy Session in Laval, Qc and announces Dr. Moutih Rafei, PhD, as a new member of the Advisory Board



Hollywood, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, and its subsidiary Cannabis Therapeutics Inc. are proud to announce that Dr. Moutih Rafei, PhD, has joined the company’s Advisory Board and that three out of the five distinguished scientists and doctors who were recently nominated to the companies’ Advisory Board will meet on Tuesday, February 28th at Le Centre Québecois d’Innovation en Biotechnologie (CQIB) in Laval, Québec, (http://www.cqib.org).

Dr. Chandra Panchal, Dr. Domenico Fuoco, and Dr. Moutih Rafei will meet at the biotech business incubator to review and discuss ETST’s ongoing R&D projects and chart the direction of the company’s research and development initiative for near future. Missing from the gathering will be Dr. Laurent Azoulay and Dr. Calvin Higgins, M.D. who cannot leave their current work at this time. Also in attendance will be Dr. Michel Aubé, PhD, CEO and Chief Scientific Officer of ETST and Cannabis Therapeutics, Inc.

At this meeting, the company will also formally launch its R&D partnership with Smart Medicine, Inc. who will provide laboratory and technical services to ETST in their facility at CQIB.

ESTS R&D is focused on the development and manufacturing of nutraceutical products, generic drugs, and cannabiniod-based medicine. The company’s goal is to market its new generic drug formulations and to find new applications for those generic drugs. The development of new improved formulations of existing generic drugs will aid in the discovery of treatment for diseases that are not currently treated with those generic drugs.

It is commonly known in the pharmacology community that most drugs act on biological targets that differ from those they were designed to treat. Drug repurposing is the name given to the process of finding new uses for existing drugs. Drug repurposing can be a very quick and economical way to bring a new, profitable drug to market. This is an important step for ETST. Existing drugs have been identified as potential ligands for the cannabinoid receptor 2 (CB2), in which ETST has a great deal of interest. Targeting CB2 with an existing drug can open up many new opportunities for the use of these existing generic drugs.

This important meeting will set the direction of ETST and Cannabis Therapeutics, Inc. and is of major interest to investors contemplating the coming cannabis investment boom.

The meeting will also be the first occasion for Dr. Moutih Rafei, the newest addition to the Advisory Board, to meet with other members.

Dr. Moutih Rafei has been an Assistant Professor in the Department of Pharmacology & Physiology of the Université de Montréal since 2013. He completed a PhD in Experimental Medicine at McGill University and his post-doctoral training in Immunobiology at the Université de Montréal. During his training, Dr. Rafei accumulated profound knowledge and insight in the fields of T-cell development and stem cell biology, cancer immunotherapy, and autoimmune diseases. He is also actively involved in the discovery and development of small molecules that may stimulate or inhibit the immune system for the treatment of certain catastrophic illnesses.

About Earth Science Tech, Inc. (ETST): Earth Science Tech (www.earthsciencetech.com) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals and Cosmeceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
Dave Demarest
(305)-546-7640

Earth Science Tech, Inc.
Nickolas S. Tabraue, P/D/COO
(305)-615-2118

Source: Earth Science Tech, Inc.

 

Earth Science Tech Initiates its Cannabis Cannabinoid-Based Composition of its 2 New Pharmaceutical Drugs and 3 Nutraceutical Patent Studies



Hollywood, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on hemp cannabinoid research and development, has begun composition work on its two (2) new Cannabis Cannabinoid-Based pharmaceutical drugs and has initiated patent studies on its three (3) new nutraceutical products. This is the first project Earth Science Tech and its wholly owned subsidiary, Cannabis Therapeutics, are working with Smart Medicines GMP on as a result of the Company’s recently finalized joint venture.

Earth Science Tech and Cannabis Therapeutics two (2) new Cannabis Cannabinoid-Based pharmaceutical drug formulations (compositions) are expected to be completed by summer 2017, with non-prescription nutraceuticals being available for sale before the end of the year and the pharmaceutical-grade products being launched in the first or second quarter of 2018.

Earth Science Tech and Cannabis Therapeutics initial patent-pending Cannabinoid-Based nutraceutical product/products being developed seek to offer a broad spectrum of health protection, including immune system strengthening properties and strong antioxidant properties among a variety of other heath & overall wellness benefits. Another nutraceutical Cannabinoid-Based product in the pipeline seeks to improve and protect brain and liver function, which can improve the quality of life for patients, especially those experiencing harsh side effects from traditional medicines. The final nutraceutical to be developed is a prophylactic that aims to prevent some of the more common causes of cancer to help reduce occurrence rates.

After the Company’s initial formulation work on the immune system-focused nutraceutical is finished, work will begin on a prescription depression, anxiety, and PTSD treatment. Once the mental illness drug formulation is finished, focus will be shifted toward developing a pharmaceutical-grade cancer treatment, with an emphasis on breast and brain cancers. Both of these pharmaceutical products will include CBD hemp oil and pure natural molecules, combined with generic drugs. Earth Science Tech and Cannabis Therapeutics look to offer patients the unique health benefits of CBD treatments with the proven backing of reliable, tried and true cancer and mental illness fighting drugs.

“We are very excited to be making such big strides in our relationship with Smart Medicines GMP after such a short time,” said CEO, Dr. Michel Aubé, “We are building products that we feel could find mass-market acceptance, as they will leverage the well-documented strengths of several existing drugs.”

Earth Science Tech and its wholly owned subsidiary, Cannabis Therapeutics, have been working zealously with Smart Medicines GMP, to invent & launch these Two (2) New Cannabinoid-based Pharmaceutical drugs and Three (3) New Advanced Cannabinoid-based Nutraceutical products using Earth Science Tech’s existing Cannabis CBD Patent, IP, Invention, Technology and future Technology. ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.

As previously announced, ETST wholly owned subsidiary, Cannabis Therapeutics, primary goal is to discover solutions for conditions for which there is presently no effective treatment as well as other medical disorders with the application of known and novel cannabis cannabinoid-based products. Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. 

ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases.

Per Earth Science Tech’s recent joint venture release with Smart Medicines GMP, Smart Medicines is equipped with a state-of-the-art laboratory and research facilities with high tech equipment and botanical extraction units. Smart Medicines will focus heavily on the research and development tasks associated with new product development. This partnership will help position Cannabis Therapeutics to be a global leader in the cannabis industry and in cannabinoid research and development. Cannabis Therapeutics’ imminent new developments and efforts have the potential to expedite our numerous upcoming cannabis cannabinoid-based therapeutic products to help aid people with certain conditions and disorders worldwide, in the later part of 2017. ETST is focused on cannabinoid-based therapeutic drugs, functional foods and nutraceuticals (retail consumer markets worldwide).

Smart Medicines is run by Dr. Domenico Fuoco, who recently joined the Advisory Board of Cannabis Therapeutics, Inc. (an Earth Science Tech subsidiary). Dr. Fuoco has over 16 years of extensive experience in developing innovative solutions for the pharmaceutical and nutraceutical industries in addition to his current status as a professional formulator. Dr. Fuoco and company’s expertise are expected to be of great benefit to Earth Science tech in its new product creation. View Dr. Fuoco’s full biography below.

Smart Medicines and Earth Science Tech have close ties with CQIB (http://www.cqib.org/home.html), a biotech and life sciences incubator. They will work closely with CQIB to improve upon and further develop their patents while developing a stronger product portfolio. This relationship will further provide both companies access to top-of-the-line research and development equipment and laboratories to provide the most accurate of results.

About Earth Science Tech, Inc. (ETST): Earth Science Tech (www.earthsciencetech.com) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals and Cosmeceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
Dave Demarest
(305)-546-7640

Earth Science Tech, Inc.
Nickolas S. Tabraue, P/D/COO
(305)-615-2118

Source: Earth Science Tech, Inc.

 

Earth Science Tech, Inc. Enters $60B Pet Industry with its Nutraceutical Scientific High Grade Hemp CBD Oil Intended for Domestic Animals



Hollywood, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company, which focuses on cannabis-industrial hemp, cannabinoid research and development, nutraceuticals and pharmaceuticals, announces it has successfully formulated and is preparing to launch a new High Grade Hemp CBD (Canabidiol) Oil formulated for domestic animals (pets), which will give the company a firm footing in the $60B pet industry.

Across the world, CBD-based pet products are seeing heightened demand. Trial studies have shown that CBD oils help reduce anxiety, inflammation, and chronic pain, while bolstering the immune system in pets. Results, have demonstrated rapid results in aiding and alleviating pets in the previously mentioned ailments, which is one of the mere reasons pet owners are eager in obtaining scientifically proven CBD wellness products from reputable and trustworthy companies.

Currently, ETST is in the process of bottling and packaging its newly developed and anticipated Nutraceutical Scientific “High Grade Hemp Pet CBD Oil” formulation (strawberry flavored), which launch date is projected late in the first quarter of the fiscal year 2017. ETST is maximizing its profitability by gaining its competitive advantage in a growing market by creating and developing a product that is not only in high demand, but that will revolutionize the ever growing market that is the pet industry. As further research and development on the benefits of “High Grade Hemp Pet CBD Oil” is conducted and a myriad of additional benefits are discovered there is no doubt that this niche market provides an opportunity to enhance and enrich the lives of pets and consequently their owners, given the fact that there are 70-80 million dogs and 74-96 million cats owned in the United States alone as per the ASPCA. View ETST’s High Grade Hemp Pet CBD product, (http://earthsciencetech.com/product/new-1-ounce-strawberry-unfiltered-high-grade-hemp-pet-cbd-250mg-cbd-oil/).

“We are thrilled to have the opportunity to get our foot in the door in this huge market and bring an innovative and helpful science based product to pet owners,” said Chief Sales Officer Gabriel Aviles, “Since we don’t currently have pet products on the market, we don’t have to worry about any sales cannibalization, just sheer growth. This is a tremendous opportunity to develop our business in two sectors at once. We look forward to updating the market in the very near term in regards to the successful launch of our pet CBD-based product and other exciting updates.”

About Earth Science Tech: (www.earthsciencetech.com) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, and Phytoceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-basedNutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore salable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (Cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Company:
Earth Science Tech
Nickolas S. Tabraue, P/D/COO
(305)-615-2118

Investor Relations
David Demarest
(305)-546-7640

Source: Earth Science Tech, Inc.

 

ETST and its wholly owned subsidiary, Cannabis Therapeutics, Signs Joint Venture with Smart Medicines GMP for the Development of its Cannabis Cannabinoid-Based Drugs & Nutraceuticals



Hollywood, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on hemp cannabinoid research and development, through its wholly owned subsidiary, Cannabis Therapeutics, Inc., recently signed a joint venture with Smart Medicines GMP, which will allow the companies to explore synergies in researching and developing new CBD-based nutraceuticals and pharmaceutical compounds based on Earth Science Tech’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” which was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil.

Smart Medicines is equipped with a state-of-the-art laboratory and research facilities with high tech equipment and botanical extraction units. Smart Medicines will focus heavily on the research and development tasks associated with new product development. This partnership will help position Cannabis Therapeutics to be a global leader in the cannabis industry and in cannabinoid research and development. Cannabis Therapeutics’ imminent new developments and efforts have the potential to expedite our numerous upcoming cannabis cannabinoid-based therapeutic products to help aid people with certain conditions and disorders worldwide, in the later part of 2017. We are focused on cannabinoid-based therapeutic drugs, functional foods and nutraceuticals (retail consumer markets worldwide).

Smart Medicines is run by Dr. Domenico Fuoco, who recently joined the Advisory Board of Cannabis Therapeutics, Inc. (an Earth Science Tech subsidiary). Dr. Fuoco has over 16 years of extensive experience in developing innovative solutions for the pharmaceutical and nutraceutical industries in addition to his current status as a professional formulator. Dr. Fuoco and company’s expertise are expected to be of great benefit to Earth Science tech in its new product creation. View Dr. Fuoco’s full biography below.

Smart Medicines and Earth Science Tech have close ties with CQIB (http://www.cqib.org/home.html), a biotech and life sciences incubator. They will work closely with CQIB to improve upon and further develop their patents while developing a stronger product portfolio. This relationship will further provide both companies access to top-of-the-line research and development equipment and laboratories to provide the most accurate of results.

“We are excited to be getting so heavily involved with Dr. Domenico Fuoco and his company, Smart Medicines GMP,” said CEO Michael Aube, “We are working hard to establish a new line of strong nutraceutical and other CBD-based products, and we think this joint venture will be very lucrative for all parties.”

Cannabis Therapeutics will work with Smart Medicines to invent and launch two new cannabinoid-based pharmaceutical drugs and three new advanced cannabinoid-based nutraceutical products using Earth Science Tech’s existing Cannabis CBD patent, IP, inventions, technology, and future technology.

Cannabis Therapeutics’ primary goal is to discover solutions for conditions for which there is presently no effective treatment as well as other medical disorders with the application of known and novel cannabis cannabinoid-based products. Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things.

ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases.

Dr. Domenico Fuoco, PhD.
Domenico Fuoco, Ph.D., has joined the Cannabis Therapeutics Inc. Advisory Board. Dr. Fuoco has over 16 years’ experience in the research and development of innovative solutions for the pharmaceutical industry. Dr. Fuoco trained at the prestigious Department of Oncology of McGill University Health Centre (MUHC) in Montreal, from 2012 to 2015. During this time, Dr. Fuoco worked on the next generation of medications for AVEO Oncology and Helsinn Therapeutics. Prior to this, Dr. Fuoco obtained his PhD and Post-Doc training in medicinal chemistry and drug discovery at the University of Perugia in Italy with further studies at the University of Salamanca School of Pharmacy in Spain.

Dr. Fuoco is recognized for the transdisciplinary approach of his work. In 2010, Dr. Fuoco was Principal Scientist of the Italian Mission in Amazonia, Bogotà, Colombia. Dr. Fuoco’s publications cover a wide-range of chemical fields, from functional foods to autoimmune diseases. In 2015, Dr. Fuoco was honored with the prestigious Dr. Henry Shibata Fellowship from the Cedar Cancer Foundation for his work in the field of palliative care. Dr. Fuoco is an active member of the Italian Canadian Community Foundation and is very active within his community. He is also the chairman from Smart Medicines Consortium for the advancement of health care.

Dr. Fuoco’s expertise in human health and functional foods are highly valued as strategic assets by Cannabis Therapeutics Inc. and ETST.

About Earth Science Tech: (www.earthsciencetech.com) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, and Phytoceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-basedNutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore salable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (Cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
Dave
(305)-546-7640

Earth Science Tech, Inc.
Nickolas S. Tabraue, P/D/COO
(305)-615-2118

Source: Earth Science Tech, Inc.

 

Earth Science Tech Strengthens Advisory Board with Four Distinguished Scientists and Doctors to Expand the Pharmaceutical & Nutraceutical Development of Cannabinoids' Therapeutic Indications, R&D, Technology, IP and Treatments



Hollywood, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company, which focuses on cannabis-industrial hemp, cannabinoid research and development, nutraceuticals and pharmaceuticals is proud to announce that four new scientists and doctors have joined the company’s Advisory Board. ETST strategy of recruiting industry experts to help expand and increase the Development of Cannabinoids' Therapeutic Indications, R&D, Technology, IP and Treatments. These Four Distinguished Scientists and Doctors will serve on the board of advisory for Earth Science Tech and or its two (2) wholly owned subsidiaries, Cannabis Therapeutics Inc., and Earth Science Pharmaceutical Inc.

Dr. Laurent Azoulay, PhD. Laurent Azoulay, Ph.D., has joined both the Cannabis Therapeutics Inc. and Earth Science Pharmaceutical Inc. Advisory Boards. He is an Associate Professor of Oncology at McGill University, where he actively researches cancer pharmacoepidemiology, which includes evaluating the safety of cancer drugs at a societal level.

After receiving his PhD in 2007 from the Université de Montréal, he completed a postdoctoral fellowship in pharmacoepidemiology at the Department of Epidemiology, Biostatistics and Occupational Health, McGill University. He then joined the Gerald Department of Oncology as an Assistant Professor in 2009. In 2016, he was promoted to the rank of Associate Professor with a cross-appointment with the Department of Epidemiology, Biostatistics and Occupational Health.

Dr. Chandra Panchal, PhD. Chandra Panchal, Ph.D., has joined the Cannabis Therapeutics Inc., Earth Science Pharmaceutical Inc., and Earth Science Tech Inc. Advisory Boards. He is a serial entrepreneur with a wealth of expertise acquired from 28 years of experience in the biotech/pharmaceutical sector.

Dr. Panchal founded Axcelon in 2001 and was a co-founder of Procyon Biopharma Inc., a publicly traded biotechnology company involved in the development of wound healing, cancer therapeutic, and diagnostic products. Now known as Ambrilia BioPharma Inc., the company listed on the Alberta Stock Exchange in 1998 and the TSX in 2000. He served as Procyon Biopharma Inc.’s Chairman, President, and CEO; and Ambrilia Biopharma Inc.’s Senior Executive Vice-President, Business Development, Licensing, and Intellectual Property in charge of both out-licensing, in-licensing and M&A activities. He retired from Ambrilia Biopharma Inc. in February 2008.

Since then, Dr. Panchal has been actively involved in Axcelon. Prior to founding Procyon Biopharma Inc., Dr. Panchal was a senior scientist/group leader supervising activities related to yeast genetics, fermentations, and product development at John Labatt Ltd., a multinational food and beverage company. Dr. Panchal sits on the board of directors of several public and private companies. He has authored/co-authored over 60 scientific papers and has edited a book entitled Yeast Strain Selection. Dr. Panchal has been an Adjunct Professor at the University of Western Ontario where he obtained his Ph.D. in biochemical engineering.

Dr. Domenico Fuoco, PhD. Domenico Fuoco, Ph.D., has joined the Cannabis Therapeutics Inc. Advisory Board. Dr. Fuoco has over 16 years’ experience in the research and development of innovative solutions for the pharmaceutical industry. Dr. Fuoco trained at the prestigious Department of Oncology of McGill University Health Centre (MUHC) in Montreal, from 2012 to 2015. During this time, Dr. Fuoco worked on the next generation of medications for AVEO Oncology and Helsinn Therapeutics. Prior to this, Dr. Fuoco obtained his PhD and Post-Doc training in medicinal chemistry and drug discovery at the University of Perugia in Italy with further studies at the University of Salamanca School of Pharmacy in Spain.

Dr. Fuoco is recognized for the transdisciplinary approach of his work. In 2010, Dr. Fuoco was Principal Scientist of the Italian Mission in Amazonia, Bogotà, Colombia. Dr. Fuoco’s publications cover a wide-range of chemical fields, from functional foods to autoimmune diseases. In 2015, Dr. Fuoco was honored with the prestigious Dr. Henry Shibata Fellowship from the Cedar Cancer Foundation for his work in the field of palliative care. Dr. Fuoco is an active member of the Italian Canadian Community Foundation and is very active within his community. He is also the chairman from Smart Medicines Consortium for the advancement of health care.

Dr. Fuoco’s expertise in human health and functional foods are highly valued as strategic assets by ETST.

Calvin Higgins, M.D.
Calvin Higgins, M.D., has joined the Earth Science Tech Inc. Advisory Board. Dr. Calvin Higgins is board-certified in internal medicine. Diplomate of the American Board of Internal Medicine. He was born in Kingston, Jamaica. He came to the United States in 1979. He attended Cornell Medical School and graduated in 1985. In 1998, he completed his residency at Lenox Hill Medical Center in Manhattan, New York in Internal Medicine. In 1998 he moved to Florida and completed 3 years in office-based medicine. He then moved onto hospital-based medicine in 2001 to present. Dr. Higgins is affiliated with Memorial Hospital Miramar, Memorial Hospital Pembroke, Memorial Hospital West and Memorial Regional Hospital.

Dr. Higgins has a great core for alternative medicine. He always encourages his patients to seek lifestyle changes in diet, exercise, meditation and mental wellness, just to name a few.

“We are very excited to have so much new talent joining our Advisory Boards,” said President, Director, and COO Nickolas Tabraue, “We are well on our way to developing top-notch treatments to some of the most common health problems people face, and bringing on such esteemed talent to advise us will only get us there quicker.”

About Earth Science Tech: (www.earthsciencetech.com) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, and Phytoceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-basedNutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore salable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (Cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Earth Science Tech, Inc.
(305)-615-2118
Nickolas S. Tabraue, P/D/COO

Source: Earth Science Tech, Inc.

 

-------------------------------------------------------------------
About Earth Science Tech, Inc.:


WWhat is ETST?

Earth Science Tech, Inc. (ETST) is a unique Science based Biotechnology company that brings Nature’s Pharmacy to the public. We are focused on developing cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals and Cosmeceuticals for the Health, Wellness and Alternative Medicine Markets that improve the quality of life for people around the world. ETST also provides natural alternatives to prescription medications through Nutritional Supplements and Dietary Supplements that help make life better for everyone and people living with common disorders and illnesses.

Nutraceuticals: A nutraceutical is a pharmaceutical-grade, medicinally or nutritionally functional food. Dr Stephen De Felice, who first used the expression nutraceutical defined it as a “food, or parts of a food, that provide medical or health benefits, including the prevention and treatment of disease”. There are sometimes different definitions of nutraceutical and functional food such as functional food is an actual, natural food that has medicinal properties, while nutraceutical is a medicinal extract taken from a natural food but sold in pill or liquid form. Example: Blueberries are a functional food. A pill or an energy drink that contains antioxidants extracted from blueberries is a nutraceutical.

Bioceuticals: Bioceuticals are natural health and wellness products, such as creams and lotions, whose active ingredients are derived from nutraceuticals

Phytoceuticals: A phytoceutical is also a form of nutraceutical. The difference is that a nutraceutical comes for a food plant, something that people regularly eat, while a phytoceutical chemical comes from a plant that is not considered part of the usual human diet.

Cosmeceuticals: Cosmeceuticals are cosmetic products that contain nutraceutical elements that deliver heath benefits along with the cosmetic use.

What are ETST Products

ETST products include CBD (Cannabidiol), a natural constituent of Hemp Oil. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD and presents a continuing stream of overwhelming evidence of significant Health and Wellness benefits including; a digestive aid that regulates appetite and eases symptoms of nausea and vomiting, analgesic pain relief, relief from anxiety, anti-tumour and anti-cancer benefits, and antipsychotic. CBD (cannabidiol) promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 “Cannabinoids as antioxidants and neuroprotectants.”
ETST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products. They come in various formulations and delivery systems such as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs.

Isn’t Hemp illegal?

Our high grade CBD (Cannabidiol) Rich Hemp oil is classified as “food based” and is therefore perfectly permissible in all 50 US states and roughly 40 countries. With no psychoactive ingredient, CBD is a ready-for-market hemp-based nutraceutical. According to our research and on-going studies with Dr Wei R. Chen, Assistant Dean of the College of Mathematics and Science at the University of Central Oklahoma, CBD has the potential to help a range of conditions and disorders.

The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be ‘food based’ and therefore saleable. The new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach.

Earth Science Tech (ETST) has the highest quality and purity, full spectrum High Grade Hemp CBD (Cannabidiol) Oil, its all natural and organic made using the world’s best supercritical CO2 liquid extraction. Our test results, research and studies with the University of Central Oklahoma and DV Biologics show we’re the leading nutritional and dietary supplement brand for High Grade Hemp CBD Oil. View our website and some of our scientific studies at: (http://www.earthsciencetech.com/scientific-research/)

More Legal Stuff

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. Cannabidiol (CBD) is a naturally occurring constituent of the industrial hemp plant and hemp oil. ETST does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US CSA). The company does sell and distribute industrial hemp-based products.

The Future for ETST

Earth Science Tech is focused on the science, research and studies of its High Grade Hemp CBD Oil as a nutraceutical and dietary supplement. In order to assure the public that ETST provides the best High Grade Hemp CBD (Cannabidiol) Oil, we continue to focus on providing the public with sound scientific research and keeping the public informed on the progression of studies being done on our High Grade Hemp CBD products. Science is what will progress the future of ETST High Grade Hemp CBD (Cannabidiol) Oil and its products. Cannabidiol (CBD) is a naturally occurring constituent of industrial hemp oil.
Join the ETST Team as a distributor or investor

Earth Science Tech currently has its Raw, Flavoured Strawberry, Flavored Peppermint High Grade Hemp CBD Oil tinctures, CBD veggie capsules, and 6 flavoured e-liquids all listed on its website for sale right now. We can provide you with single tinctures and bulk tinctures as well as bulk wholesale oil, powder, vape oil, formulations and more. We really tend to cater to our partners more than any other company out there and we take a personal approach. We are here to help you with your overall health and wellness needs.

Earth Science Tech, Inc. is a publicly traded company under ETST

Earth Science Tech (ETST) Scientific Research, Studies, Data and News on ETST High Grade Hemp CBD (Cannabidiol) Oil:

February 23, 2017 – Earth Science Tech Initiates its Cannabis Cannabinoid-Based Composition of its 2 New Pharmaceutical Drugs and 3 Nutraceutical Patent Studies

April 29, 2016 – Earth Science Tech Announces Strategic Alliance with Septembers Mission Foundation to Conduct its First 30-Day Ten Participant Clinical Study with 9/11 First Responders using ETST High Grade Hemp CBD (Cannabidiol) Oil

April 11, 2016 – Earth Science Tech, Inc Announces Positive Results from First Pre-Clinical Study on New Hampshire Participate #1 of Dysfunctional Veterans with PTSD (Posttraumatic Stress Disorder) using ETST High Grade Hemp CBD (Cannabidiol)

March 28, 2016 – Earth Science Tech Announces Strategic Alliance with RRNP Healthcare and Dysfunctional Veterans of New Hampshire to conduct its First 30-Day PTSD Clinical Study with Veterans using ETST High Grade Hemp CBD (Cannabidiol) Oil

Febuary 3, 2016 – Earth Science Tech Supported Positive Scientific Research Studies and Customer Feedback on its Phytocannabinoid-CBD (Cannabidiol) Rich Hemp Oil Prompts Company to Launch Non-Profit Phytocannabinoid-CBD Research Foundation

December 9, 2015 – Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol)

November 19, 2015 – Earth Science Tech Announces Positive Interim results from Trial with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol)

October 29, 2015 – Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol)

October 20, 2015 – Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection

October 16, 2015 – Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD)

August 18, 2015 – DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant

June 23, 2015 – DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro

May 29, 2015 – Earth Science Tech, Inc. (ETST) Announces Positive Progress on Its High Grade CBD (Cannabidiol) Rich Hemp Oil in vitro Studies on Various Human Primary Cells with DV Biologics, a Leading Biological Company

April 13, 2015 – ETST and DV Biologics Begin Testing ETST CBD (Cannabidiol) Rich Hemp Oil In Vitro on Various Human Primary Cells to See if it Serves as a Neuroprotectant Which May Help With Neurodegenerative Disorders

January 26, 2015 – Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function

January 16, 2015- Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD (Cannabidiol) Rich Hemp Oil Because of Its Findings With the University of Central Oklahoma and the Effects of CBD on Immune Cells

November 3, 2014 – Earth Science Tech Enters Stage 2 of Research on Its Hemp Oil Enriched With CBD (Cannabidiol) on Immune Cells and Announces Multiple Patents and Clinical Trials of the CBD-Cannabinoid Compounds

October 20, 2014 – Earth Science Tech Announces and Secures New Provisional Patent for Hemp Oil Enriched With CBD (Cannabidiol) Filed With the United States Patent and Trademark Office (USPTO)
October 9, 2014 – Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells

Septermber 22, 2014 – ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells

.SOURCE: http://earthsciencetech.com/




Disclaimer

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated three thousand nine hundred dollars for Earth Science Tech, Inc.. coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF Earth Science Tech, Inc.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.